Printer Friendly

NEW CANCER GENETHERAPY IS GOAL OF PROJECT BY CISTRON BIOTECHNOLOGY AND GENETIC THERAPY

 NEW CANCER GENETHERAPY IS GOAL OF PROJECT
 BY CISTRON BIOTECHNOLOGY AND GENETIC THERAPY
 PINE BROOK, N.J. March 31 /PRNewswire/ -- Genetic Therapy, Inc. (NASDAQ: GTII) and Cistron Biotechnology, Inc. have entered into an agreement that could produce a new approach to the treatment of cancer.
 The announcement was made by Bruce C. Galton, Cistron president and chief operating officer, and Dr. M. James Barrett, Genetic Therapy president and chief executive officer.
 Under the contract, Cistron has licensed the right to develop and market commercial products using its genetic code for Interleukin 1-b and other Cistron proprietary information to Genetic Therapy, Inc. (GTI). Financial terms of the agreement were not revealed.
 Through its research, which will involve human clinical trials, GTI will attempt to strengthen the ability of cancer patients to successfully stop the spread of the disease in their bodies.
 The process will involve stimulating cancer patients' immune systems, and thus their ability to deter cancer's growth. The gene for Cistron's Interleukin 1-b will be inserted into patients' cancerous cells in the hope that the cells quickly recognize and destroy other new cancer cells.
 Cistron's IL-1b assay kits will be used by GTI during the development and human clinical phases.
 Cistron's primary product area is immune response regulators, known as lymphokines. The company manufactures and sells lymphokine assay kits to pharmaceutical companies and academic institutions in the United States, Europe and the Far East for cancer, arthritis and other autoimmune disease research.
 The company is currently expanding its product line and has initiated research on IL-1b inhibitors. An effective inhibitor could reduce inflammation and possible bone and cartilage deterioration in such autoimmune diseases as rheumatoid arthritis and lupus.
 Genetic Therapy, Inc., based in Gaithersburg, Md., is a leader in the development of delivery systems for human gene therapy for genetic and acquired diseases. Founded in 1986, GTI and its collaborators represent one of the largest groups of scientists dedicated to research and development in this field. GTI's shares have been publicly traded since July 1991.
 -0- 3/31/92
 /CONTACT: Harold Smith of Hal Smith Associates, 201-305-0244, for Genetic Therapy/
 (GTII) CO: Genetic Therapy, Inc.; Cistron Biotechnology, Inc. ST: New Jersey, Maryland IN: MTC SU: JVN


PS -- NY008 -- 3224 03/31/92 08:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1992
Words:375
Previous Article:MARK IV REPORTS RECORD SALES AND INCOME FROM OPERATIONS IN FISCAL YEAR AND FOURTH QUARTER
Next Article:HBO TO LAUNCH PAY-TV SERVICE IN SINGAPORE
Topics:


Related Articles
CISTRON WILL USE EQUITY AGREEMENT PROCEEDS TO EXPAND INTERLEUKIN-1 INHIBITOR RESEARCH PROGRAM
CISTRON SUES PEPROTECH FOR INTERLEUKIN-1 PATENT INFRINGEMENT
CISTRON ANNOUNCES INCREASED THIRD QUARTER EARNINGS AND SALES
CISTRON BIOTECHNOLOGY SUES IMMUNEX CORP. OVER INTERLEUKIN-1b PATENT
CISTRON BIOTECHNOLOGY REPORTS SALES INCREASE FOR SECOND QUARTER AND SIX MONTHS
/C O R R E C T I O N -- IMMUNEX/CISTRON/(Correction Notice)
CISTRON ANNOUNCES RESULTS FOR SECOND QUARTER
CISTRON-IMMUNEX TRIAL WILL BE RESCHEDULED TO SEPTEMBER
Henry Grausz Resigns as Chairman and Director of Cistron Biotechnology
Cistron Biotechnology Retains BlueStone Capital Partners as Its Financial Advisor

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters